Welcome to our dedicated page for Silexion Therapeutics SEC filings (Ticker: SLXNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Silexion Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Silexion Therapeutics's regulatory disclosures and financial reporting.
Silexion Therapeutics Corp is calling an extraordinary general meeting on July 13, 2026 to seek shareholder approval for two capital-related proposals tied to its Nasdaq listing and clinical funding needs.
The first proposal asks shareholders to approve the exercisability of 399,020 new Series C and D warrants at $5.00 per share and 13,966 placement agent warrants at $6.25 per share that were issued in a May 18, 2026 warrant inducement financing which raised about $1.0 million and helped restore compliance with Nasdaq’s $2.5 million shareholders’ equity requirement.
The second proposal would increase authorized share capital by 10,000,000 ordinary shares to a total of 15,900,000 shares, giving Silexion more capacity to issue equity for financings, operations and potential business development while maintaining its Nasdaq Capital Market listing as it begins Phase 2/3 trials for SIL‑204.
Silexion Therapeutics Corp is calling an extraordinary general meeting on July 13, 2026 to seek shareholder approval for two capital-related proposals tied to its Nasdaq listing and clinical funding needs.
The first proposal asks shareholders to approve the exercisability of 399,020 new Series C and D warrants at $5.00 per share and 13,966 placement agent warrants at $6.25 per share that were issued in a May 18, 2026 warrant inducement financing which raised about $1.0 million and helped restore compliance with Nasdaq’s $2.5 million shareholders’ equity requirement.
The second proposal would increase authorized share capital by 10,000,000 ordinary shares to a total of 15,900,000 shares, giving Silexion more capacity to issue equity for financings, operations and potential business development while maintaining its Nasdaq Capital Market listing as it begins Phase 2/3 trials for SIL‑204.
Silexion Therapeutics Corp files a shelf registration to register the resale by selling shareholders of up to 859,609 ordinary shares, comprising up to 399,020 shares issuable upon new warrants, 13,966 placement agent warrant shares and up to 446,623 shares issuable upon conversion of the Sponsor Promissory Note.
The prospectus states the company will receive no proceeds from sales by the selling shareholders, though it may receive cash proceeds if warrants are exercised for cash. The filing discloses recent financings (an inducement warrant exercise raising ~$1.0M, ATM sales of ~$1.75M net aggregate through June 10, 2026), a 1-for-10 reverse split in May 2026, restored Nasdaq shareholders' equity compliance above the $2.5M minimum, and ongoing Nasdaq monitoring until September 23, 2026.
Silexion Therapeutics Corp files a shelf registration to register the resale by selling shareholders of up to 859,609 ordinary shares, comprising up to 399,020 shares issuable upon new warrants, 13,966 placement agent warrant shares and up to 446,623 shares issuable upon conversion of the Sponsor Promissory Note.
The prospectus states the company will receive no proceeds from sales by the selling shareholders, though it may receive cash proceeds if warrants are exercised for cash. The filing discloses recent financings (an inducement warrant exercise raising ~$1.0M, ATM sales of ~$1.75M net aggregate through June 10, 2026), a 1-for-10 reverse split in May 2026, restored Nasdaq shareholders' equity compliance above the $2.5M minimum, and ongoing Nasdaq monitoring until September 23, 2026.
Silexion Therapeutics Corp reported that CSO and CDO Shirvan Mitchell received a grant of 6,000 Ordinary Shares via fully vested restricted share units, settled immediately in respect of his services as an officer and approved by the board of directors. Following this grant, he directly holds 8,789 Ordinary Shares.
The filing also updates option holdings after a 1-for-10 reverse share split effective on May 28, 2026. Mitchell now holds options to purchase 48 Ordinary Shares at an exercise price of $9,077.10 per share, expiring on June 7, 2032.
Silexion Therapeutics Corp reported that CSO and CDO Shirvan Mitchell received a grant of 6,000 Ordinary Shares via fully vested restricted share units, settled immediately in respect of his services as an officer and approved by the board of directors. Following this grant, he directly holds 8,789 Ordinary Shares.
The filing also updates option holdings after a 1-for-10 reverse share split effective on May 28, 2026. Mitchell now holds options to purchase 48 Ordinary Shares at an exercise price of $9,077.10 per share, expiring on June 7, 2032.
Horenshtein Hadar Mirit reported acquisition or exercise transactions in this Form 4 filing.
Silexion Therapeutics Corp reported that its CFO and Secretary, Hadar Mirit Horenshtein, received a grant of 7,500 fully vested restricted share units that were immediately settled into ordinary shares, at a stated price of $0.00 per share, for service as an officer. Following this award, the reporting person directly holds 12,515 ordinary shares. A prior 1-for-10 reverse share split on May 28, 2026 adjusted earlier beneficial holdings from 50,146 ordinary shares at $0.0135 par value to 5,015 ordinary shares at $0.135 par value before this grant.
Horenshtein Hadar Mirit reported acquisition or exercise transactions in this Form 4 filing.
Silexion Therapeutics Corp reported that its CFO and Secretary, Hadar Mirit Horenshtein, received a grant of 7,500 fully vested restricted share units that were immediately settled into ordinary shares, at a stated price of $0.00 per share, for service as an officer. Following this award, the reporting person directly holds 12,515 ordinary shares. A prior 1-for-10 reverse share split on May 28, 2026 adjusted earlier beneficial holdings from 50,146 ordinary shares at $0.0135 par value to 5,015 ordinary shares at $0.135 par value before this grant.
Silexion Therapeutics Corp reported that Chairman and CEO Hadar Ilan received a grant of 10,000 ordinary shares at no cost, delivered through fully vested restricted share units for services as an officer and approved by the board. After this award, Ilan directly holds 16,547 ordinary shares. The Form 4 also updates a stock option position to 96 options for 96 ordinary shares at an exercise price of $9,077.10 per share, reflecting a 1-for-10 reverse share split completed on May 28, 2026. The option holdings are shown for informational purposes, with no new option transactions reported.
Silexion Therapeutics Corp reported that Chairman and CEO Hadar Ilan received a grant of 10,000 ordinary shares at no cost, delivered through fully vested restricted share units for services as an officer and approved by the board. After this award, Ilan directly holds 16,547 ordinary shares. The Form 4 also updates a stock option position to 96 options for 96 ordinary shares at an exercise price of $9,077.10 per share, reflecting a 1-for-10 reverse share split completed on May 28, 2026. The option holdings are shown for informational purposes, with no new option transactions reported.
Moringa Sponsor, LP and related parties filed Amendment No. 2 to their Schedule 13D on Silexion Therapeutics Corp. They report beneficial ownership of 1,382,346 ordinary shares, representing 32.99% of Silexion’s ordinary shares outstanding, calculated using 4,189,954 shares reported in Silexion’s Form 10-Q as of March 31, 2026.
The reported holdings include 6,970 ordinary shares, 372 ordinary shares underlying warrants, 450,000 ordinary shares issued on September 15, 2025 upon conversion of $1.8 million under an Amended and Restated Promissory Note, and 925,004 ordinary shares issued on May 14, 2026 upon conversion of $0.4 million under the same note. The reporting persons state they are filing out of an abundance of caution and expressly dispute the validity of the 450,000 and 925,004 shares and do not concede beneficial ownership of them.
Moringa Sponsor, LP and related parties filed Amendment No. 2 to their Schedule 13D on Silexion Therapeutics Corp. They report beneficial ownership of 1,382,346 ordinary shares, representing 32.99% of Silexion’s ordinary shares outstanding, calculated using 4,189,954 shares reported in Silexion’s Form 10-Q as of March 31, 2026.
The reported holdings include 6,970 ordinary shares, 372 ordinary shares underlying warrants, 450,000 ordinary shares issued on September 15, 2025 upon conversion of $1.8 million under an Amended and Restated Promissory Note, and 925,004 ordinary shares issued on May 14, 2026 upon conversion of $0.4 million under the same note. The reporting persons state they are filing out of an abundance of caution and expressly dispute the validity of the 450,000 and 925,004 shares and do not concede beneficial ownership of them.
Silexion Therapeutics Corp has implemented a 1-for-10 reverse share split of its ordinary shares to help maintain compliance with Nasdaq’s minimum bid price requirements. The split became effective after the close of business on May 28, 2026, with trading on a split-adjusted basis beginning May 29, 2026 under the existing symbol SLXN.
Following the reverse split, authorized share capital remains at $796,500, now divided into 5,900,000 ordinary shares with par value increasing from $0.0135 to $0.135 per share. As of April 7, 2026, issued shares were consolidated from 4,074,710 to 407,471. The company also adjusted its public and private warrants so each whole warrant now reflects the 1-for-10 ratio and carries an exercise price of $15,525.00 per ordinary share, with no fractional shares issued on exercise.
Silexion Therapeutics Corp has implemented a 1-for-10 reverse share split of its ordinary shares to help maintain compliance with Nasdaq’s minimum bid price requirements. The split became effective after the close of business on May 28, 2026, with trading on a split-adjusted basis beginning May 29, 2026 under the existing symbol SLXN.
Following the reverse split, authorized share capital remains at $796,500, now divided into 5,900,000 ordinary shares with par value increasing from $0.0135 to $0.135 per share. As of April 7, 2026, issued shares were consolidated from 4,074,710 to 407,471. The company also adjusted its public and private warrants so each whole warrant now reflects the 1-for-10 ratio and carries an exercise price of $15,525.00 per ordinary share, with no fractional shares issued on exercise.
Silexion Therapeutics Corp is implementing a 1-for-10 reverse share split of its ordinary shares. The split becomes effective after market close on May 28, 2026, with shares trading on a reverse split-adjusted basis on the Nasdaq Capital Market from May 29, 2026 under the symbol SLXN.
Every ten ordinary shares will be automatically combined into one share, and the par value will increase from $0.0135 to $0.135 per share. No fractional shares will be issued; eligible DTC participants will have any fractional entitlements rounded up to the nearest whole share. The company states that the reverse split is intended, among other things, to help maintain compliance with Nasdaq’s minimum bid price requirement and support its strategic plans as it advances its RNAi candidate SIL204 toward a Phase 2/3 trial in locally advanced pancreatic cancer.
Silexion Therapeutics Corp is implementing a 1-for-10 reverse share split of its ordinary shares. The split becomes effective after market close on May 28, 2026, with shares trading on a reverse split-adjusted basis on the Nasdaq Capital Market from May 29, 2026 under the symbol SLXN.
Every ten ordinary shares will be automatically combined into one share, and the par value will increase from $0.0135 to $0.135 per share. No fractional shares will be issued; eligible DTC participants will have any fractional entitlements rounded up to the nearest whole share. The company states that the reverse split is intended, among other things, to help maintain compliance with Nasdaq’s minimum bid price requirement and support its strategic plans as it advances its RNAi candidate SIL204 toward a Phase 2/3 trial in locally advanced pancreatic cancer.
Silexion Therapeutics Corp filed Amendment No. 1 to its annual report for the year ended December 31, 2025. The amendment is narrowly focused on correcting typographical errors in Item 9A so that the date of management’s evaluation of internal control over financial reporting is properly stated as December 31, 2025 rather than December 31, 2024.
Management, including the Chief Executive Officer and Chief Financial Officer, evaluated disclosure controls and procedures and internal control over financial reporting as of December 31, 2025 using the COSO 2013 framework and concluded both were effective. As a non-accelerated, emerging growth company, Silexion is not required to obtain an auditor attestation on internal control.
The company states there were no changes in internal control over financial reporting during the three-month period ended December 31, 2025 that materially affected, or are reasonably likely to materially affect, these controls. Other disclosures from the original Form 10-K remain unchanged, aside from updated exhibits and certifications. As of June 30, 2025, non-affiliate ordinary shares had an aggregate market value of $6,619,600, and 3,330,785 ordinary shares were outstanding as of March 10, 2026.
Silexion Therapeutics Corp filed Amendment No. 1 to its annual report for the year ended December 31, 2025. The amendment is narrowly focused on correcting typographical errors in Item 9A so that the date of management’s evaluation of internal control over financial reporting is properly stated as December 31, 2025 rather than December 31, 2024.
Management, including the Chief Executive Officer and Chief Financial Officer, evaluated disclosure controls and procedures and internal control over financial reporting as of December 31, 2025 using the COSO 2013 framework and concluded both were effective. As a non-accelerated, emerging growth company, Silexion is not required to obtain an auditor attestation on internal control.
The company states there were no changes in internal control over financial reporting during the three-month period ended December 31, 2025 that materially affected, or are reasonably likely to materially affect, these controls. Other disclosures from the original Form 10-K remain unchanged, aside from updated exhibits and certifications. As of June 30, 2025, non-affiliate ordinary shares had an aggregate market value of $6,619,600, and 3,330,785 ordinary shares were outstanding as of March 10, 2026.
Silexion Therapeutics reported first quarter 2026 results and highlighted progress for its lead RNAi candidate SIL204 in locally advanced pancreatic cancer. The Israeli Ministry of Health approved initiation of a Phase 2/3 clinical trial, and a Clinical Trial Application was submitted in Germany under the EU Clinical Trials Regulation, keeping trial initiation on track for the second quarter of 2026.
For the three months ended March 31, 2026, Silexion recorded a net loss of $2.7 million compared with $1.7 million a year earlier, driven by higher research and development expense of $1.4 million and general and administrative expense of $1.4 million. Cash and cash equivalents declined to $2.4 million from $6.0 million as of December 31, 2025, while shareholders’ equity fell to $0.3 million from $2.6 million, and a related party promissory note of $1.6 million was reclassified into current liabilities. Management noted warrant exercise inducements, at-the-market usage and shareholder approval for a prospective reverse share split as steps to support both clinical development and continued Nasdaq listing.
Silexion Therapeutics reported first quarter 2026 results and highlighted progress for its lead RNAi candidate SIL204 in locally advanced pancreatic cancer. The Israeli Ministry of Health approved initiation of a Phase 2/3 clinical trial, and a Clinical Trial Application was submitted in Germany under the EU Clinical Trials Regulation, keeping trial initiation on track for the second quarter of 2026.
For the three months ended March 31, 2026, Silexion recorded a net loss of $2.7 million compared with $1.7 million a year earlier, driven by higher research and development expense of $1.4 million and general and administrative expense of $1.4 million. Cash and cash equivalents declined to $2.4 million from $6.0 million as of December 31, 2025, while shareholders’ equity fell to $0.3 million from $2.6 million, and a related party promissory note of $1.6 million was reclassified into current liabilities. Management noted warrant exercise inducements, at-the-market usage and shareholder approval for a prospective reverse share split as steps to support both clinical development and continued Nasdaq listing.